Evidence map›Paper›PMID 32500763›Full record

ReviewExpert review of vaccines2020

Recent advances in human norovirus research and implications for candidate vaccines.

Jordan E Cates, Jan Vinjé, Umesh Parashar, Aron J Hall

Open access · greenAbstract readReview
In one paragraph

Review in Expert review of vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Symptomatic and Asymptomatic Norovirus Infections in Early Life; the PREVAIL Cohort, 2017-2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  4. Review
  5. Wastewater-based surveillance of norovirus GI and GII: Comparative performance of commercial and in-house RT-qPCR Assays.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  6. Article
  7. Article
  8. [Development of a Reverse Transcription Loop-Mediated Isothermal Amplification Assay for the Detection of Genogroup Ⅱ Norovirus].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. INTRA- AND INTER-HOST EVOLUTION OF HUMAN NOROVIRUS IN HEALTHY ADULTS.bioRxiv : the preprint server for biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jordan E CatesDivision of Viral Diseases, Centers for Disease Control and Prevention , Atlanta, GA, USA.
Jan VinjéDivision of Viral Diseases, Centers for Disease Control and Prevention , Atlanta, GA, USA.
Umesh ParasharDivision of Viral Diseases, Centers for Disease Control and Prevention , Atlanta, GA, USA.
Aron J HallDivision of Viral Diseases, Centers for Disease Control and Prevention , Atlanta, GA, USA.
Centers for Disease Control and Prevention · USEpidemic Intelligence Service · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

introductionNoroviruses are a leading cause of acute gastroenteritis worldwide. An estimated 21 million illnesses in the United States and upwards of 684 million illnesses worldwide are attributed to norovirus infection. There are no licensed vaccines to prevent norovirus, but several candidates are in development. AREAS COVERED: We review recent advances in molecular epidemiology of noroviruses, immunology, and in-vitro cultivation of noroviruses using human intestinal enteroids. We also provide an update on the status of norovirus vaccine candidates. EXPERT OPINION: Molecular epidemiological studies confirm the tremendous genetic diversity of noroviruses, the continuous emergence of new recombinant strains, and the predominance of GII.4 viruses worldwide. Duration of immunity, extent of cross protection between different genotypes, and differences in strain distribution for young children compared with adults remain key knowledge gaps. Recent discoveries regarding which epitopes are targeted by neutralizing antibodies using the novel in vitro culture of human noroviruses in human intestinal enteroids are enhancing our understanding of mechanisms of protection and providing guidance for vaccine development. A future norovirus vaccine has the potential to substantially reduce the burden of illnesses due to this ubiquitous virus.

Indexed as

AdultAnimalsAntibodies, NeutralizingCaliciviridae InfectionsChildEpitopesGastroenteritisGenotypeHumansNorovirusViral VaccinesAntibodies, NeutralizingEpitopesViral Vaccinesacute gastroenteritisimmunologyNorovirusvaccine development

Identifiers

PMID32500763
PMCPMC10760411
OpenAlexW3033959592

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.